JAZZ Jazz Pharmaceuticals plc

NEUTRAL Impact: 3/10 144
Horizon days Filed Jun 1, 2026 Processed 11d 12h ago SEC 0001628280-26-039499
Form 144 — notice of proposed sale of securities
Latest settled — T+1d ⚠ clustered
JAZZ ▲ +2.13% at T+1d
NEUTRAL call ✓ call won +2.13% · α vs SPY +2.85% · entry $226.12 → $230.93
Next anchor: T+5d due 5d ago
Currently $230.56 · +1.96% from $226.12 entry
Entry anchored
Jun 1, 2026
via day open
T+1d
+2.13%
call +2.13% · α +2.85%
$230.93
settled 11d ago
T+5d
call — · α —
due 5d ago
T+20d
call — · α —
in 17d
T+60d
call — · α —
in 2mo

Price Chart

Loading chart...

Executive Summary

Bruce C. Cozadd, Chairman and CEO of Jazz Pharmaceuticals, filed a Form 144 on June 1, 2026, indicating intent to sell 6,000 shares of common stock. At the filing date, the proposed sale value was approximately $1.41 million, representing a modest portion of his likely total holdings. The filing is a routine insider sale notice and does not signal material concern given the CEO's ongoing role and the relatively small size relative to market cap.

Actionable Insight

This is a routine insider sale notice from the CEO. The 6,000-share amount is small relative to his likely holdings and the company's market cap. No immediate trading action warranted; monitor for any subsequent Form 4 filings to confirm execution and for any pattern of larger sales.

Key Facts

  • Filer: Bruce C. Cozadd, Chairman and CEO of Jazz Pharmaceuticals
  • Proposed sale: 6,000 shares of common stock
  • Estimated value at filing: ~$1,410,720 (based on $235.12/share)
  • Shares to be sold from stock options exercised on 03/05/2022
  • Broker: Merrill Lynch
  • Filing date: June 1, 2026; proposed sale date same day
  • Recent insider activity (30d): 4 sells totaling $3.1M

Financial Impact

Proposed sale of 6,000 shares valued at ~$1.41M, representing approximately 0.01% of Jazz's $14.8B market cap

dilution

Risk Factors

  • CEO selling could be misinterpreted as lack of confidence, though the small size mitigates this
  • If this is part of a 10b5-1 plan, the signal is further neutralized

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
92% bullish (24 analysts)

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001628280-26-039499
Document: 0001628280-26-039499-index.html0001628280-26-039499
Document: 0001628280-26-039499.txt0001628280-26-039499
14 reports for JAZZ
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for JAZZ — sortable, filterable
Type Now
Jun 8, 2026
4d ago
DEFA14A
NEUTRAL ★ 3/10
$231.98 awaiting T+1awaiting T+1$230.56 (−0.61%)
Jun 3, 2026
9d ago
Insider Cluster
BEARISH ★ 5/10
$239.17 $238.57▲ +0.25%▼ −2.32%$230.56 (+3.60%)
Jun 3, 2026
9d ago
Insider Cluster
NEUTRAL ★ 3/10
$240.06 $238.57▼ −0.62%▲ +1.98%$230.56 (−3.96%)
Jun 1, 2026
11d ago
144
NEUTRAL ★ 3/10
$226.12 $230.93▲ +2.13%▲ +2.85%$230.56 (+1.96%)
May 29, 2026
14d ago
8-K
NEUTRAL ★ 2/10
$231.19 $226.12▼ −2.19%▼ −2.34%$230.56 (−0.27%)
May 1, 2026
6w ago
144
NEUTRAL ★ 2/10
$202.51 $207.89▲ +2.66%▲ +3.00%$230.56 (+13.85%)
Apr 24, 2026
7w ago
10-K/A
NEUTRAL ★ 4/10
$200.31 $203.07▲ +1.38%▲ +1.86%$230.56 (+15.10%)
Apr 1, 2026
10w ago
144
NEUTRAL ★ 3/10
$186.73 $185.83▼ −0.48%▼ −0.96%$230.56 (+23.47%)
Feb 27, 2026
15w ago
Insider Cluster
NEUTRAL ★ 3/10
$189.00 $190.30▲ +0.69%▲ +0.63%$230.56 (+21.99%)
Feb 27, 2026
15w ago
Insider Cluster
NEUTRAL ★ 3/10
$189.00 $190.30▲ +0.69%▲ +0.63%$230.56 (+21.99%)
Showing 10 of 14

US Market Status

Market Closed — Opens Mon (52h 18m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access